Partnership Programs to Reduce Cardiovascular Disparities- Morehouse- Emory Partnership (Meta-Health)

This study has been completed.
Sponsor:
Collaborators:
Morehouse School of Medicine
Information provided by (Responsible Party):
Arshed A. Quyyumi, Emory University
ClinicalTrials.gov Identifier:
NCT00336869
First received: June 12, 2006
Last updated: November 15, 2013
Last verified: November 2013
  Purpose

The theme of this Morehouse-Emory Partnership Program focuses on elucidating the etiologic basis of ethnic differences in obesity-related CVD and discovering new intervention strategies to ameliorate CV health in all communities. The proposed Program uses a multi-disciplinary strategy to systematically characterize ethnic differences in obesity-related CVD by drawing upon the fields of physiology, psychology, biochemistry, vascular biology, public health, nursing and clinical medicine.


Condition Phase
Metabolic Syndrome
Phase 2

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Partnership Programs to Reduce Cardiovascular Disparities- Morehouse- Emory Partnership

Resource links provided by NLM:


Further study details as provided by Emory University:

Biospecimen Retention:   Samples Without DNA

Blood samples metabolic testing


Enrollment: 680
Study Start Date: December 2005
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Detailed Description:

Emerging evidence indicates that there are ethnicity-specific differences in the profile of biochemical, metabolic and physiological perturbations associated with obesity. The implications of these ethnic differences remain to be further defined. Several epidemiologic studies have shown that vascular disease and its cardiovascular complications, carry significantly higher morbidity and mortality in African Americans compared with Caucasians.1-3 These observations may be partly explained by a higher prevalence of cardiovascular disease risk factors, such as essential hypertension, diabetes mellitus, and tobacco use among African Americans.4-6 However, the pathophysiological processes underlying this racial predisposition have not been fully elucidated.7 It is likely that the etiologic basis of ethnic disparities in cardiovascular disease is multi-factorial and involves dynamic gene-environment interactions in which variances in behavior and the social context are critical determinants.

The proposed Program recognizes the importance of incorporating both biological factors and social determinants in the analysis of cardiovascular disparities

  Eligibility

Ages Eligible for Study:   30 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

African American and White residents age 30-65

Criteria

Inclusion Criteria:

Our methodological approach will involve a random digit-dialing cross-sectional survey of 4000 Metro Atlanta area AA and white residents (ages 30-65 years). This aim will focus on using well-validated survey instruments to examine self-reported perceptions of psychosocial stress, neighborhood segregation factors and health beliefs related to weight/weight control. These parameters will be assessed in relation to the differential prevalence of three major outcomes: (1) self-reported maladaptive cardiovascular behaviors that predispose to obesity-related CVD (ie high fat/sodium and low fruit/vegetables dietary intake and physical inactivity); (2) obesity; and (3) hypertension.

This study will address the following research questions: Are the observed racial differences in maladaptive health behaviors (diet/inactivity) and MetS components (obesity, hypertension) associated with: a) perceived psychosocial stress, and if so, does depression, neighborhood factors or health beliefs around weight and weight control modify this relationship?

-

Exclusion Criteria:

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00336869

Locations
United States, Georgia
Emory GCRC
Atlanta, Georgia, United States, 30329
Morehouse CRC
Atlanta, Georgia, United States, 30310
Sponsors and Collaborators
Emory University
Morehouse School of Medicine
Investigators
Principal Investigator: Arshed Quyyumi, MD Emory University
Principal Investigator: Gary Gibbons, MD Morehouse School of Medicine
  More Information

No publications provided

Responsible Party: Arshed A. Quyyumi, Professor, Emory University
ClinicalTrials.gov Identifier: NCT00336869     History of Changes
Other Study ID Numbers: IRB00024856, 1024-2004
Study First Received: June 12, 2006
Last Updated: November 15, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Metabolic Syndrome X
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on September 18, 2014